The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Why do SGLT2 inhibitors reduce heart failure hospitalization? Adifferential volume regulation hypothesis
Open accessAbstract
The effect of a sodium glucose cotransporter 2 inhibitor (SGLT2i) in reducing heart failure hospitalization in the EMPA‐REG OUTCOMES trial has raised the possibility of using these agents to treat established heart failure. We hypothesize that osmotic diuresis induced by SGLT2 inhibition, a distinctly different diuretic mechanism than that of other diuretic classes, results in greater electrolyte‐free water clearance and, ultimately, in greater fluid clearance from the interstitial fluid (IF) space than from the circulation, potentially resulting in congestion relief with minimal impact on blood volume, arterial filling and organ perfusion. We utilize a mathematical model to illustrate that electrolyte‐free water clearance results in a greater reduction in IF volume compared to blood volume, and that this difference may be mediated by peripheral sequestration of osmotically inactive sodium. By coupling the model with data on plasma and urinary sodium and water in healthy subjects who received either the SGLT2i dapagliflozin or loop diuretic bumetanide, we predict that dapagliflozin produces a 2‐fold greater reduction in IF volume compared to blood volume, while the reduction in IF volume with bumetanide is only 78% of the reduction in blood volume. Heart failure is characterized by excess fluid accumulation, in both the vascular compartment and interstitial space, yet many heart failure patients have arterial underfilling because of low cardiac output, which may be aggravated by conventional diuretic treatment. Thus, we hypothesize that, by reducing IF volume to a greater extent than blood volume, SGLT2 inhibitors might provide better control of congestion without reducing arterial filling and perfusion.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“SGLT-2i has a role of improving the multi-functional status of cardiovascular activities, although the diuretics seem to elicit a more powerful effect on reducing fluid retention.64,65”
From Dapagliflozin Activates Neurons in the Central Nervous System and Regulates Cardiovascular Activity by Inhibiting SGLT-2 in Mice (2020) · cites this paper as [64]
In the citing paper
“In addition, a study that coupled plasma and urinary water and electrolyte data with mathematical modeling to compare effects of dapagliflozin and bumetanide on volumes of blood and interstitial fluid suggested that SGLT2 inhibitors have a preferential effect to mobilize fluid from the interstitial compartment rather than the intravascular space (38).”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [38]
In the citing paper
“Mathematical analyses suggest that the excess electrolyte-free water clearance associated with osmotic diuresis may result in greater clearance of interstitial fluid compared with other forms of diuretics (14).”
From Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data (2018) · cites this paper as [14]
In the citing paper
“This suggests that the capacity to store Na ϩ peripherally is associated with an ability to clear interstitial fluid, as we have described previously (14).”
From Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data (2018) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
Ferrannini, E., Mark, M., & Mayoux, E. (2016) · Diabetes Care · doi:10.2337/dc16-0330 · Cited by 975
Fitchett, D., Zinman, B., Wanner, C., Lachin, J. M., Hantel, S., Salsali, A., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Inzucchi, S. E. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv728 · Cited by 907
Francis, G. S., SIEGEL, R. M., Goldsmith, S. R., OLIVARI, M. T., Levine, T. B., & Cohn, J. N. (1985) · Annals of Internal Medicine · doi:10.7326/0003-4819-103-1-1 · Cited by 577
Aggravated renal dysfunction during intensive therapy for advanced chronic heart failure
Weinfeld, M. S., Chertow, G. M., & Stevenson, L. W. (1999) · American Heart Journal · doi:10.1016/s0002-8703(99)70113-4 · Cited by 279
Peacock, W. F., Costanzo, M. R., Marco, T. D., Lopatin, M., Wynne, J., Mills, R. M., & Emerman, C. L. (2008) · Cardiology · doi:10.1159/000164149 · Cited by 263
Body Fluid Volume Regulation in Health and Disease: A Unifying Hypothesis
Schrier, R. W. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-113-2-155 · Cited by 263
Skin Sodium Concentration Correlates with Left Ventricular Hypertrophy in CKD
Schneider, M. P., Raff, U., Kopp, C., Scheppach, J. B., Toncar, S., Wanner, C., Schlieper, G., Saritas, T., Floege, J., Schmid, M., et al. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016060662 · Cited by 195
Greenberg, A. (2000) · The American Journal of the Medical Sciences · doi:10.1016/s0002-9629(15)40676-7 · Cited by 154
Flagged first, then by citations
Cited by
Sorted by citations
SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
Verma, S., & McMurray, J. J. V. (2018) · Diabetologia · doi:10.1007/s00125-018-4670-7 · Cited by 999
Self-citationMechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors
Lopaschuk, G. D., & Verma, S. (2020) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2020.02.004 · Cited by 941
SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control
Cowie, M., & Fisher, M. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0406-8 · Cited by 829
Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors
Zelniker, T. A., & Braunwald, E. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.11.031 · Cited by 596
Petrie, M. C., Verma, S., Docherty, K. F., Inzucchi, S. E., Anand, I., Belohlávek, J., Böhm, M., Chiang, C.-E., Chopra, V. K., de Boer, R. A., et al. (2020) · JAMA · doi:10.1001/jama.2020.1906 · Cited by 531
Self-citationEffects of SGLT2 Inhibitors on Kidney and Cardiovascular Function
Vallon, V., & Verma, S. (2020) · Annual Review of Physiology · doi:10.1146/annurev-physiol-031620-095920 · Cited by 556
McMurray, J. J. V., DeMets, D. L., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Langkilde, A. M., Martinez, F. A., Bengtsson, O., Ponikowski, P., Sabatine, M. S., et al. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1432 · Cited by 433
Self-citationCongestion in heart failure: a contemporary look at physiology, diagnosis and treatment
Boorsma, E. M., ter Maaten, J. M., Damman, K., Dinh, W., Gustafsson, F., Goldsmith, S. R., Burkhoff, D., Zannad, F. M., Udelson, J. E., & Voors, A. A. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0379-7 · Cited by 379
Cardiovascular Effects of New Oral Glucose-Lowering Agents
Scheen, A. J. (2018) · Circulation Research · doi:10.1161/circresaha.117.311588 · Cited by 292
An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors
Salvatore, T., Galiero, R., Caturano, A., Rinaldi, L., Martino, A. D., Albanese, G., Salvo, J. D., Epifani, R., Marfella, R., Docimo, G., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073651 · Cited by 279
Anker, S. D., Butler, J., Filippatos, G. S., Jamal, W., Salsali, A., Schnee, J. M., Kimura, K. A., Zeller, C., George, J. T., Brueckmann, M., et al. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1596 · Cited by 250
Mordi, N., Mordi, I. R., Singh, J. S., McCrimmon, R. J., Struthers, A. D., & Lang, C. C. (2020) · Circulation · doi:10.1161/circulationaha.120.048739 · Cited by 248
Herrington, W. G., Preiss, D., Haynes, R., von Eynatten, M., Staplin, N., Hauske, S. J., George, J. T., Green, J. B., Landray, M. J., Baigent, C., et al. (2018) · Clinical Kidney Journal · doi:10.1093/ckj/sfy090 · Cited by 237
SGLT2i: beyond the glucose-lowering effect
Ni, L., Yuan, C., Chen, G., Zhang, C., & Wu, X. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01071-y · Cited by 240
Sarafidis, P. A., Ferro, C. J., Morales, E., Ortíz, A., Małyszko, J., Hojs, R., Khazim, K., Ekart, R., Valdivielso, J. M., Fouque, D. P., et al. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfy407 · Cited by 216
Ikonomidis, I., Pavlidis, G., Thymis, J., Birba, D., Kalogeris, A., Kousathana, F., Kountouri, A., Balampanis, K., Parissis, J., Andreadou, I., et al. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.015716 · Cited by 199
Rangaswami, J., Bhalla, V., de Boer, I. H., Staruschenko, A., Sharp, J. A., Singh, R. R., Lo, K. B., Tuttle, K., Vaduganathan, M., Ventura, H., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000920 · Cited by 192
JCS/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure
Tsutsui, H., Ide, T., Ito, H., Kihara, Y., Kinugawa, K., Kinugawa, S., Makaya, M., Murohara, T., Node, K., Saito, Y., et al. (2021) · Circulation Journal · doi:10.1253/circj.cj-21-0431 · Cited by 191
SGLT‐2 Inhibitors in Heart Failure: Current Management, Unmet Needs, and Therapeutic Prospects
Lam, C. S. P., Chandramouli, C., Ahooja, V., & Verma, S. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.013389 · Cited by 200
Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure
Joshi, S. S., Singh, T., Newby, D. E., & Singh, J. S. (2021) · Heart · doi:10.1136/heartjnl-2020-318060 · Cited by 191
Kidney and heart failure outcomes associated with SGLT2 inhibitor use
der Beek, A. B. V. D. A., de Boer, R. A., & Heerspink, H. J. L. (2022) · Nature Reviews Nephrology · doi:10.1038/s41581-022-00535-6 · Cited by 186
Jackson, A. M., Dewan, P., Anand, I. S., Bělohlávek, J., Bengtsson, O., de Boer, R. A., Böhm, M., Boulton, D. W., Chopra, V. K., DeMets, D. L., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.047077 · Cited by 175
Self-citationObesity-Related Heart Failure With a Preserved Ejection Fraction
Packer, M., & Kitzman, D. W. (2018) · JACC: Heart Failure · doi:10.1016/j.jchf.2018.01.009 · Cited by 172
Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload
Packer, M., Anker, S. D., Butler, J., Filippatos, G. S., Ferreira, J. P., Pocock, S., Sattar, N. A., Brueckmann, M., Jamal, W., Cotton, D., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.01.033 · Cited by 172
Schernthaner, G., Shehadeh, N., As, A., Bazarova, A., Ebrahimi, F., Fasching, P., Janež, A., Kempler, P., Konrāde, I., Lalic, N. M., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01154-w · Cited by 163
JCS/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure
Tsutsui, H., Ide, T., Ito, H., Kihara, Y., Kinugawa, K., Kinugawa, S., Makaya, M., Murohara, T., Node, K., Saito, Y., et al. (2021) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2021.04.023 · Cited by 166
Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure
Boorsma, E. M., Beusekamp, J. C., ter Maaten, J. M., Figarska, S. M., Danser, A. H. J., van Veldhuisen, D. J., van der Meer, P., Heerspink, H. J. L., Damman, K., & Voors, A. A. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.2066 · Cited by 165
Heerspink, H. J. L., Kiyosue, A., Wheeler, D. C., Lin, M., Wijkmark, E., Carlson, G. F., Mercier, A., Åstrand, M., Ueckert, S., Greasley, P. J., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)02230-4 · Cited by 150
Self-citationSeferovic, P. M., Fragasso, G., Petrie, M. C., Müllens, W., Ferrari, R., Thum, T., Bauersachs, J. K., Anker, S. D., Ray, R., Çavuşoğlu, Y., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1954 · Cited by 136
Tuttle, K. R., Brosius, F. C., Cavender, M. A., Fioretto, P., Fowler, K. J., Heerspink, H. J. L., Manley, T., McGuire, D. K., Molitch, M. E., Mottl, A. K., et al. (2020) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2020.08.003 · Cited by 135
SGLT2 Inhibitors and Their Mode of Action in Heart Failure—Has the Mystery Been Unravelled?
Pabel, S., Hamdani, N., Luedde, M., & Sossalla, S. T. (2021) · Current Heart Failure Reports · doi:10.1007/s11897-021-00529-8 · Cited by 142
Packer, M., Wilcox, C. S., & Testani, J. M. (2023) · Circulation · doi:10.1161/circulationaha.123.064346 · Cited by 126
Scholtes, R. A., Muskiet, M. H. A., van Baar, M. J. B., Hesp, A. C., Greasley, P. J., Karlsson, C., Hammarstedt, A., Arya, N., van Raalte, D. H., & Heerspink, H. J. L. (2021) · Diabetes Care · doi:10.2337/dc20-2604 · Cited by 125
Self-citationDapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists
Shen, L., Kristensen, S. L., Bengtsson, O., Böhm, M., de Boer, R. A., Docherty, K. F., Inzucchi, S. E., Katova, T., Køber, L., Kosiborod, M., et al. (2021) · JACC Heart Failure · doi:10.1016/j.jchf.2020.11.009 · Cited by 125
Self-citationTuttle, K. R., Brosius, F. C., Cavender, M. A., Fioretto, P., Fowler, K. J., Heerspink, H. J. L., Manley, T., McGuire, D. K., Molitch, M. E., Mottl, A. K., et al. (2021) · Diabetes · doi:10.2337/dbi20-0040 · Cited by 123
Jensen, J., Omar, M., Kistorp, C., Tuxen, C., Gustafsson, I., Køber, L., Gustafsson, F., Faber, J. O., Malik, M. E., Fosbøl, E. L., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30382-x · Cited by 119
Management of post‐transplant diabetes: immunosuppression, early prevention, and novel antidiabetics
Hecking, M., Sharif, A., Eller, K., & Jenssen, T. G. (2020) · Transplant International · doi:10.1111/tri.13783 · Cited by 115
Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects
Palmiero, G., Cesaro, A., Vetrano, E., Pafundi, P. C., Galiero, R., Caturano, A., Moscarella, E., Gragnano, F., Salvatore, T., Rinaldi, L., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115863 · Cited by 124
Dapagliflozin vs. metolazone in heart failure resistant to loop diuretics
Yeoh, S. E., Osmanska, J., Petrie, M. C., Brooksbank, K. J. M., Clark, A. L., Docherty, K. F., Foley, P. W. X., Guha, K., Halliday, C. A., Jhund, P. S., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad341 · Cited by 110
Self-citationDekkers, C. C. J., Sjöström, C. D., Greasley, P. J., Cain, V., Boulton, D. W., & Heerspink, H. J. L. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13855 · Cited by 106
Self-citationSGLT2-inhibitors; more than just glycosuria and diuresis
Fathi, A., Vickneson, K., & Singh, J. S. (2021) · Heart Failure Reviews · doi:10.1007/s10741-020-10038-w · Cited by 109
Effect of Empagliflozin on Hemodynamics in Patients With Heart Failure and Reduced Ejection Fraction
Omar, M., Jensen, J., Frederiksen, P. H., Kistorp, C., Videbæk, L. M., Poulsen, M. K., Möller, S., Ali, M., Gustafsson, F., Køber, L., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.10.005 · Cited by 106
Applications of SGLT2 inhibitors beyond glycaemic control
O’Hara, D. V., Lam, C. S. P., McMurray, J. J. V., Yi, T. W., HOCKING, S. L., Dawson, J., Raichand, S., Januszewski, A. S., & Jardine, M. (2024) · Nature Reviews Nephrology · doi:10.1038/s41581-024-00836-y · Cited by 123
Self-citationState-of-the-Art-Review: Mechanisms of Action of SGLT2 Inhibitors and Clinical Implications
Vallon, V. (2024) · American Journal of Hypertension · doi:10.1093/ajh/hpae092 · Cited by 119
SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses
Filippatos, T. D., Liontos, A., Papakitsou, I., & Elisaf, M. (2019) · Postgraduate Medicine · doi:10.1080/00325481.2019.1581971 · Cited by 109
Effect of dapagliflozin on anaemia in DAPA‐HF
Docherty, K. F., Curtain, J. P., Anand, I. S., Bengtsson, O., Inzucchi, S. E., Køber, L., Kosiborod, M., Langkilde, A. M., Martínez, F. A., Ponikowski, P. P., et al. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2132 · Cited by 104
Self-citationMolecular Mechanisms of SGLT2 Inhibitor on Cardiorenal Protection
Hou, Y., Zheng, C., Yen, T., & Lu, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21217833 · Cited by 110
Packer, M. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13229 · Cited by 105
Nguyen, T., Wen, S., Gong, M., Yuan, X., Xu, D., Wang, C., Jin, J., & Zhou, L. (2020) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s258593 · Cited by 97
Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism
Tang, J., Ye, L., Yan, Q., Zhang, X., & Wang, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.800490 · Cited by 106
Packer, M. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1732 · Cited by 100
Mason, T., Coelho‐Filho, O. R., Verma, S., Chowdhury, B., Zuo, F., Quan, A., Thorpe, K. E., Bonneau, C., Teoh, H., Gilbert, R. E., et al. (2021) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2020.10.017 · Cited by 96
Clegg, L. E., Penland, R. C., Bachina, S., Boulton, D. W., Thuresson, M., Heerspink, H. J. L., Gustavson, S., Sjöström, C. D., Ruggles, J. A., Hernandez, A. F., et al. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0942-x · Cited by 94
Self-citationEffects of Dapagliflozin on Volume Status When Added to Renin–Angiotensin System Inhibitors
Eickhoff, M. K., Dekkers, C. C. J., Kramers, B. J., Laverman, G. D., Frimodt‐Møller, M., Jørgensen, N. R., Faber, J. O., Danser, A. H. J., Gansevoort, R. T., Rossing, P. R., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8060779 · Cited by 93
SGLT2 Inhibitors as Potential Anticancer Agents
Basak, D., Gamez, D., & Deb, S. (2023) · Biomedicines · doi:10.3390/biomedicines11071867 · Cited by 87
Packer, M. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvaa064 · Cited by 86
Giorgino, F., Vora, J. P., Fenici, P., & Solini, A. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01163-9 · Cited by 88
Cardiorenal Syndrome: The Role of Neural Connections Between the Heart and the Kidneys
Patel, K. P., Katsurada, K., & Zheng, H. (2022) · Circulation Research · doi:10.1161/circresaha.122.319989 · Cited by 90
Potential Mechanisms of Sodium-Glucose Co-Transporter 2 Inhibitor-Related Cardiovascular Benefits
Verma, S. (2019) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2019.10.028 · Cited by 87
Garg, V., Verma, S., & Connelly, K. (2019) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2019.07.005 · Cited by 82
Zheng, R., Wang, Y., Tang, J., Duan, J.-Y., Yuan, M.-Y., & Zhang, J. (2021) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001183 · Cited by 90
Kasiakogias, A., Rosei, E. A., Camafort, M., Ehret, G., Faconti, L., Ferreira, J. P., Brguljan-Hitij, J., Januszewicz, A., Kahan, T., Manolis, A. J., et al. (2021) · Journal of Hypertension · doi:10.1097/hjh.0000000000002910 · Cited by 81
Chen, X., Hocher, C., Shen, L., Krämer, B. K., & Hocher, B. (2023) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00177.2023 · Cited by 79
Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes
Davies, M. J., Drexel, H., Jornayvaz, F. R., Pataky, Z., Seferovic, P. M., & Wanner, C. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01575-9 · Cited by 80
Helmlinger, G., Sokolov, V. V., Peskov, K. V., Hallow, K. M., Kosinsky, Y., Voronova, V., Chu, L., Yakovleva, T. A., Azarov, I., Kaschek, D., et al. (2019) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12426 · Cited by 76
Self-citationWater Conservation Overrides Osmotic Diuresis During SGLT2 Inhibition in Patients With Heart Failure
Marton, A., Saffari, S. E., Rauh, M., Sun, R.-N., Nagel, A. M., Linz, P. R., Lim, T. T., Takase‐Minegishi, K., Pajarillaga, A., Saw, S., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.02.020 · Cited by 78
Self-citationNatali, A., Nesti, L., Tricò, D., & Ferrannini, E. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01385-5 · Cited by 70
Tamargo, J. L. (2019) · European Cardiology Review · doi:10.15420/ecr.2018.34.2 · Cited by 72
Hwang, I., Cho, G., Yoon, Y. E., Park, J. J., Park, J., Lee, S., Kim, H., Kim, Y.-J., & Sohn, D. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01042-3 · Cited by 68
Cardiovascular Benefits from Gliflozins: Effects on Endothelial Function
Salvatore, T., Caturano, A., Galiero, R., Martino, A. D., Albanese, G., Vetrano, E., Sardu, C., Marfella, R., Rinaldi, L., & Sasso, F. C. (2021) · Biomedicines · doi:10.3390/biomedicines9101356 · Cited by 72
Hallow, K. M., Greasley, P. J., Helmlinger, G., Chu, L., Heerspink, H. J., & Boulton, D. W. (2018) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00202.2018 · Cited by 68
Self-citationRau, M., Thiele, K., Hartmann, N. K., Schuh, A., Altiok, E., Möllmann, J., Keszei, A. P., Böhm, M., Marx, N., & Lehrke, M. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01175-5 · Cited by 68
Empagliflozin restores the integrity of the endothelial glycocalyx in vitro
Cooper, S., Teoh, H., Campeau, M.-A., Verma, S., & Leask, R. L. (2019) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-019-03555-2 · Cited by 71
Packer, M. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.120.016270 · Cited by 66
Leccisotti, L., Cinti, F., Sorice, G. P., D’Amario, D., Lorusso, M., Guzzardi, M. A., Mezza, T., Gugliandolo, S., Cocchi, C., Capece, U., et al. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01607-4 · Cited by 69
Bashier, A. M., Hussain, A. K. B., Abdelgadir, E., Alawadi, F., Sabbour, H. M., & CHILTON, R. J. (2019) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-019-0476-0 · Cited by 63
SGLT2 inhibitors: the future for treatment of type 2 diabetes mellitus and other chronic diseases
Wanner, C., & Marx, N. (2018) · Diabetologia · doi:10.1007/s00125-018-4678-z · Cited by 65
Fediuk, D. J., Nucci, G., Dawra, V. K., Cutler, D. L., Amin, N. B., Terra, S. G., Boyd, R. A., Krishna, R., & Sahasrabudhe, V. (2020) · Clinical Pharmacokinetics · doi:10.1007/s40262-020-00875-1 · Cited by 66
Wang, C., Chen, C., Lin, M.-H., Su, H., Ho, M.-Y., Yeh, J., Tsai, M., Hsieh, C., & Wen, M. (2020) · Biology · doi:10.3390/biology9110369 · Cited by 63
Scheen, A. J. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.06.008 · Cited by 65
SGLT-2 inhibitors as cardio-renal protective agents
Caruso, I., & Giorgino, F. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154937 · Cited by 62
Oxidative stress as a culprit in diabetic kidney disease
Su, S., Ma, Z., Wu, H., Xu, Z., & Yi, H. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121661 · Cited by 62
Mechanisms and Evidence for Heart Failure Benefits from SGLT2 Inhibitors
Wójcik, C., & Warden, B. A. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1219-4 · Cited by 62
Delanaye, P., & Scheen, A. J. (2021) · Diabetes & Metabolism · doi:10.1016/j.diabet.2021.101285 · Cited by 64
Iacobellis, G., & Baroni, M. G. (2021) · Journal of Endocrinological Investigation · doi:10.1007/s40618-021-01687-1 · Cited by 61
Biegus, J., Fudim, M., Salah, H. M., Heerspink, H. J. L., Voors, A. A., & Ponikowski, P. P. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.2967 · Cited by 57
Mechanisms of SGLT2 Inhibitors in Heart Failure and Their Clinical Value
Xie, Y., Wei, Y., Li, D., Pu, J., Ding, H., & Zhang, X. (2023) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001380 · Cited by 58
Katsurada, K., Nandi, S. S., Sharma, N. M., & Patel, K. P. (2021) · Circulation Heart Failure · doi:10.1161/circheartfailure.121.008365 · Cited by 57
DAPA-HF trial: dapagliflozin evolves from a glucose-lowering agent to a therapy for heart failure
Kaplinsky, E. (2020) · Drugs in Context · doi:10.7573/dic.2019-11-3 · Cited by 64
Effects of Empagliflozin on Fluid Overload, Weight, and Blood Pressure in CKD
Mayne, K. J., Staplin, N., Keane, D. F., Wanner, C., Brenner, S., Cejka, V., Stegbauer, J., Judge, P. K., Preiss, D., Emberson, J., et al. (2023) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000000000271 · Cited by 58
Margonato, D., Galati, G., Mazzetti, S., Cannistraci, R., Perseghin, G., Margonato, A., & Mortara, A. (2020) · Heart Failure Reviews · doi:10.1007/s10741-020-10024-2 · Cited by 54
Carvalho, P. E. P., Veiga, T. M. A., Silva, A. C. S. E., Gewehr, D. M., Dagostin, C. S., Fernandes, A. D. F., Nasi, G. M., & Cardoso, R. N. (2023) · Clinical Research in Cardiology · doi:10.1007/s00392-022-02148-2 · Cited by 55
Butler, J., Handelsman, Y., Bakris, G. L., & Verma, S. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1708 · Cited by 54
Jensen, J., Omar, M., Kistorp, C., Poulsen, M. K., Tuxen, C., Gustafsson, I., Køber, L., Gustafsson, F., Fosbøl, E. L., Bruun, N. E., et al. (2019) · Trials · doi:10.1186/s13063-019-3474-5 · Cited by 52
Ujjawal, A., Schreiber, B., & Verma, A. (2022) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188221090001 · Cited by 53
Anti-Oxidative Therapy in Diabetic Nephropathy
Hernandez, L. F., Eguchi, N., Whaley, D., Alexander, M., Tantisattamo, E., & Ichii, H. (2022) · Frontiers in Bioscience-Scholar · doi:10.31083/j.fbs1402014 · Cited by 52
Bertoccini, L., & Baroni, M. G. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/5584_2020_494 · Cited by 49
SGLT2 inhibition and adipose tissue metabolism: current outlook and perspectives
Morciano, C., Gugliandolo, S., Capece, U., Giuseppe, G. D., Mezza, T., Ciccarelli, G., Soldovieri, L., Brunetti, M., Avolio, A., Splendore, A., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02539-x · Cited by 52
Bonora, B. M., Cappellari, R., Albiero, M., Avogaro, A., & Fadini, G. P. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00824 · Cited by 48
Metadata
- Authors
- Hallow, K. M., Helmlinger, G., Greasley, P. J., McMurray, J. J. V., & Boulton, D. W.
- Affiliations
- University of Georgia (US)
- AstraZeneca (United States) (US)
- AstraZeneca (Sweden) (SE)
- University of Glasgow (GB)
- Corresponding author
- Hallow, Karen M.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2017-11-15
- Volume
- 20
- Issue
- 3
- Pages
- 479-487
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2763866789
- Cited by
- 499
- References
- 24
- Citations by year
- 2026: 36 · 2025: 50 · 2024: 46 · 2023: 75 · 2022: 65 · 2021: 89 · 2020: 76 · 2019: 44 · 2018: 15
- FWCI
- 28.74
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Obesity and Metabolism (publishedVersion)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- Research Bank (Australian Catholic University) (submittedVersion)
- Funders
- AstraZeneca
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ion Transport and Channel Regulation
- Keywords
- SGLT2 inhibitors, dapagliflozin, heart failure hospitalization, interstitial fluid volume, osmotic diuresis, fluid congestion, loop diuretics, bumetanide, EMPA-REG OUTCOME
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Adult, Benzhydryl Compounds, Blood Volume, Bumetanide, Diuresis, Diuretics, Drug Combinations, Drug Interactions, Female, Glucosides, Heart Failure, Hospitalization, Humans, Male, Middle Aged, Osmolar Concentration, Sodium, Water-Electrolyte Imbalance, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
